BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 03/03/23

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products, is working on changing the grim reality caused by the evolution of COVID-19. “The company’s leading inhaled nanosized antibody (‘N...

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercial...

Age-related macular generation is an ocular disease that causes a reduction in central vision as individuals grow older. The condition is caused when a region of the retina called the macular becomes damaged and causes patients to lose the ability to see fine details; it can also be referred to ...

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical ...

BiondVax Pharmaceuticals is promoting preclinical results of its lead “biobetter” NanoAb drug candidate for conveniently proactively preventing COVID The company’s CEO recently presented the data at the annual BIO CEO & Investor Conference in New York, as well as update...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently achieved key milestones. These include the demonstration of statistically si...

Psoriasis is a skin condition that causes flaky skin patches which form scales. The condition’s symptoms include dry skin lesions called plaques, which can appear anywhere on one’s body, including the knees, elbows, lower back and scalp. While the condition’s primary cau...

Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8 His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19...

Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to m...

The COVID-19 pandemic was a major reminder of just how problematic infectious diseases can be, especially if we aren’t intimately aware of their spread patterns. Only a few months after the disease was discovered in Wuhan, China , significant chunks of the world were shut down to avoid ...